135.90

0.75% -1.03

After Hours: 135.90

Ascendis Pharma A/S ADR (ASND)

Overview News Price History Option Chain Why ASND Down? Discussions Forecast

Ascendis Pharma A/S ADR stock is currently priced at $135.90, with a 24-hour trading volume of 225.35K. It has seen a -0.75% decreased in the last 24 hours and a -9.38% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $138.0 pivot point. If it approaches the $135.1 support level, significant changes may occur.

Previous Close:

$136.93

Open:

$137

24h Volume:

225.35K

Market Cap:

$7.69B

Revenue:

$288.35M

Net Income/Loss:

$-521.73M

P/E Ratio:

-12.01

EPS:

-11.3176

Net Cash Flow:

$-508.61M

1W Performance:

-3.05%

1M Performance:

-9.38%

6M Performance:

+52.70%

1Y Performance:

+77.79%

1D Range:

$133.39

$139.81

52W Range:

$66.03

$161.00

Ascendis Pharma A/S ADR Stock (ASND) Company Profile

Name

Ascendis Pharma A/S ADR

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

45 70 22 22 44

Address

Tuborg Boulevard 5, Hellerup

Employee

137

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

ASND's Discussions on Twitter

Ascendis Pharma A/S ADR Stock (ASND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Initiated	Jefferies	Buy
Jun-14-23	Resumed	Credit Suisse	Neutral
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Aug-30-22	Resumed	Berenberg	Buy
Mar-28-22	Resumed	Wedbush	Outperform
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy
Mar-01-22	Initiated	Citigroup	Buy
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-06-22	Initiated	Cowen	Market Perform
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Mar-20-20	Initiated	Oppenheimer	Outperform
Oct-11-19	Initiated	Morgan Stanley	Overweight
Mar-25-19	Initiated	Evercore ISI	Outperform
Jan-24-19	Initiated	Cantor Fitzgerald	Overweight
Jan-24-19	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-18	Initiated	Stifel	Buy
Apr-02-18	Reiterated	Leerink Partners	Mkt Perform
May-11-17	Initiated	JP Morgan	Overweight
Mar-09-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Feb-09-17	Initiated	Credit Suisse	Outperform
Sep-26-16	Initiated	Wedbush	Outperform

View All

Ascendis Pharma A/S ADR Stock (ASND) Latest News

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

GlobeNewswire Inc.

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks Investment Research

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

GlobeNewswire Inc.

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Zacks Investment Research

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Zacks Investment Research

Ascendis Pharma A/S ADR Stock (ASND) Financials Data

Ascendis Pharma A/S ADR (ASND) Revenue 2024

ASND reported a revenue (TTM) of $288.35 million for the quarter ending December 31, 2023, a +443.66% rise year-over-year.

Ascendis Pharma A/S ADR (ASND) Net Income 2024

ASND net income (TTM) was -$521.73 million for the quarter ending December 31, 2023, a +14.43% increase year-over-year.

Ascendis Pharma A/S ADR (ASND) Cash Flow 2024

ASND recorded a free cash flow (TTM) of -$508.61 million for the quarter ending December 31, 2023, a +5.47% increase year-over-year.

Ascendis Pharma A/S ADR (ASND) Earnings per Share 2024

ASND earnings per share (TTM) was -$9.2761 for the quarter ending December 31, 2023, a +14.67% growth year-over-year.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.